<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34369907</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-712X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>5</Issue>
            <PubDate>
              <MedlineDate>2021 Sep-Oct 01</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical psychopharmacology</Title>
          <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perphenazine-Associated Nausea: A Case of Protracted Withdrawal.</ArticleTitle>
        <Pagination>
          <StartPage>606</StartPage>
          <EndPage>608</EndPage>
          <MedlinePgn>606-608</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001436</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Nirmal</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sood</LastName>
            <ForeName>Natasha</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jolly</LastName>
            <ForeName>Taranjeet</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8109496</NlmUniqueID>
        <ISSNLinking>0271-0749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FTA7XXY4EZ</RegistryNumber>
          <NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34369907</ArticleId>
        <ArticleId IdType="doi">10.1097/JCP.0000000000001436</ArticleId>
        <ArticleId IdType="pii">00004714-900000000-98268</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Magalotti SR, Neudecker M, Zaraa SG, et al. Understanding chronic aggression and its treatment in children and adolescents. Curr Psychiatry Rep. 2019;21:123.</Citation>
        </Reference>
        <Reference>
          <Citation>Nevels RM, Dehon EE, Alexander K, et al. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol. 2010;18:184–201.</Citation>
        </Reference>
        <Reference>
          <Citation>Hirsch GS. Dosing and monitoring: children and adolescents. Psychopharmacol Bull. 2018;48:34–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10:193–200.</Citation>
        </Reference>
        <Reference>
          <Citation>Dilsaver SC, Alessi NE. Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand. 1988;77:241–246.</Citation>
        </Reference>
        <Reference>
          <Citation>Clow A, Theodorou A, Jenner P, et al. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol. 1980;63:145–157.</Citation>
        </Reference>
        <Reference>
          <Citation>Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977;196:326–328.</Citation>
        </Reference>
        <Reference>
          <Citation>Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186:S256–S261.</Citation>
        </Reference>
        <Reference>
          <Citation>Stedman TJ, Whiteford HA. Dopaminergic supersensitivity and vomiting among schizophrenic patients. Acta Psychiatr Scand. 1990;81:94–95.</Citation>
        </Reference>
        <Reference>
          <Citation>Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20:195–201.</Citation>
        </Reference>
        <Reference>
          <Citation>Jolly T, Waxmonsky J, Baweja R. Lisdexamfetamine-associated tonsure trichotillomania. J Clin Psychopharmacol. 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Lako IM, van den Heuvel ER, Knegtering H, et al. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33:675–681.</Citation>
        </Reference>
        <Reference>
          <Citation>Leucht S, Crippa A, Siafis S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177:342–353.</Citation>
        </Reference>
        <Reference>
          <Citation>Horowitz MA, Murray RM, Taylor D. Tapering antipsychotic treatment. JAMA Psychiat. 2021;78:125–126.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34369907</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-712X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>5</Issue>
            <PubDate>
              <MedlineDate>2021 Sep-Oct 01</MedlineDate>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical psychopharmacology</Title>
          <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perphenazine-Associated Nausea: A Case of Protracted Withdrawal.</ArticleTitle>
        <Pagination>
          <StartPage>606</StartPage>
          <EndPage>608</EndPage>
          <MedlinePgn>606-608</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001436</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Nirmal</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sood</LastName>
            <ForeName>Natasha</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jolly</LastName>
            <ForeName>Taranjeet</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8109496</NlmUniqueID>
        <ISSNLinking>0271-0749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FTA7XXY4EZ</RegistryNumber>
          <NameOfSubstance UI="D010546">Perphenazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010546" MajorTopicYN="N">Perphenazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34369907</ArticleId>
        <ArticleId IdType="doi">10.1097/JCP.0000000000001436</ArticleId>
        <ArticleId IdType="pii">00004714-900000000-98268</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Magalotti SR, Neudecker M, Zaraa SG, et al. Understanding chronic aggression and its treatment in children and adolescents. Curr Psychiatry Rep. 2019;21:123.</Citation>
        </Reference>
        <Reference>
          <Citation>Nevels RM, Dehon EE, Alexander K, et al. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol. 2010;18:184–201.</Citation>
        </Reference>
        <Reference>
          <Citation>Hirsch GS. Dosing and monitoring: children and adolescents. Psychopharmacol Bull. 2018;48:34–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10:193–200.</Citation>
        </Reference>
        <Reference>
          <Citation>Dilsaver SC, Alessi NE. Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand. 1988;77:241–246.</Citation>
        </Reference>
        <Reference>
          <Citation>Clow A, Theodorou A, Jenner P, et al. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol. 1980;63:145–157.</Citation>
        </Reference>
        <Reference>
          <Citation>Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977;196:326–328.</Citation>
        </Reference>
        <Reference>
          <Citation>Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186:S256–S261.</Citation>
        </Reference>
        <Reference>
          <Citation>Stedman TJ, Whiteford HA. Dopaminergic supersensitivity and vomiting among schizophrenic patients. Acta Psychiatr Scand. 1990;81:94–95.</Citation>
        </Reference>
        <Reference>
          <Citation>Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20:195–201.</Citation>
        </Reference>
        <Reference>
          <Citation>Jolly T, Waxmonsky J, Baweja R. Lisdexamfetamine-associated tonsure trichotillomania. J Clin Psychopharmacol. 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Lako IM, van den Heuvel ER, Knegtering H, et al. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33:675–681.</Citation>
        </Reference>
        <Reference>
          <Citation>Leucht S, Crippa A, Siafis S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177:342–353.</Citation>
        </Reference>
        <Reference>
          <Citation>Horowitz MA, Murray RM, Taylor D. Tapering antipsychotic treatment. JAMA Psychiat. 2021;78:125–126.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
